Neurocrine Biosciences | الأصول





الأصول تغيير تاريخ
AbbVie USD 133.96B 62M 2025-12
Acadia Pharmaceuticals USD 1.33B 105.22M 2025-09
Agios Pharmaceuticals USD 1.3B 88.48M 2025-12
ALKERMES USD 2.33B 76.7M 2025-09
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
Amgen USD 90.59B 445M 2025-12
Biogen USD 29.44B 232M 2025-12
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Cytokinetics USD 1.44B 210.92M 2025-09
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Exelixis USD 2.84B 20.87M 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
Halozyme Therapeutics USD 2.53B 304.09M 2025-12
Incyte USD 6.96B 627.62M 2025-12
Ionis Pharmaceuticals USD 3.03B 47.96M 2025-09
Nektar Therapeutics USD 301.35M 93.81M 2025-09
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
Pfizer USD 208.73B 2.64B 2025-09
Prothena USD 352.63M 46.44M 2025-09
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Repligen USD 2.92B 22.08M 2025-09
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
Sarepta Therapeutics USD 3.49B 186.38M 2025-09
Teva Pharmaceutical Industries USD 40.75B 892M 2025-12
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
Vertex Pharmaceuticals USD 25.64B 780.7M 2025-12
Xoma USD 263.15M 39.7M 2025-09


Neurocrine Biosciences الأصول - القيم الحالية، والبيانات التاريخية، والتنبؤات والإحصاءات والرسوم البيانية والتقويم الاقتصادي - Feb 2026.